October 19, 2022
NOT-OD-21-013 - Final NIH Policy for Data Management and Sharing
National Cancer Institute (NCI)
The National Cancer Institute (NCI) is seeking input on the use and reuse of cancer metabolomics data. Review of this entire RFI notice is encouraged to ensure a comprehensive response is prepared and to have a full understanding of how your response will be used.
The NCI is seeking input on best practices for cancer metabolomics data storage, management, and use/reuse. Progress in cancer research requires that data is generated via rigorous methods and reported in a complete and transparent way, both to facilitate reproducibility and allow opportunities for reuse in secondary analyses. In alignment with both FAIR (Findable, Accessible, Interoperable, and Reusable) principles and the new NIH policy for Data Management and Sharing (NOT-OD-21-013), a thoughtful assessment of how to address the data management needs of the cancer metabolomics community is critical and timely. Deposition of and access to metabolomics datasets and related code in a way that safeguards the privacy of de-identified clinical data, supports reproducibility, and provides for reuse and harmonization across datasets, particularly in the context of multi-omics and high-throughput integrative analyses, will expand the utility of these data and maximize NIH investments in this area.
This RFI is intended to assist NCI in identifying, developing, and implementing strategies that will speed progress in cancer metabolomics by ensuring that data generated by funded projects is accessible and maximally useful to the entire cancer research community. This RFI invites participation from stakeholders across the cancer research, metabolomics, and data management fields.
Metabolomics is important to cancer researchers in many different fields, including those who work on:
NCI seeks information from practitioners in these and other relevant fields. Comments may address, but are not limited to, one or more of the following bulleted topics:
Submitting a response
All responses must be submitted electronically on the submission website.
Responses must be received by 11:59:59 pm (ET) on December 23, 2022
Responses to this RFI are voluntary. Do not include any proprietary, classified, confidential, trade secret, or sensitive information in your response. The responses will be reviewed by NIH staff, and individual feedback will not be provided to any responder. The Government will use the information submitted in response to this RFI at its discretion. Any identifiers (e.g., names, institutions, e-mail addresses, etc.) will be removed when responses are compiled. The Government reserves the right to use only the processed, anonymized results on public NIH websites, in reports, in summaries of the state of the science, in any possible resultant solicitation(s), grant(s), or cooperative agreement(s), or in the development of future funding opportunity announcements.
This RFI is for information and planning purposes only and shall not be construed as a solicitation, grant, or cooperative agreement, or as an obligation on the part of the Federal Government, the NIH, or individual NIH Institutes and Centers to provide support for any ideas identified in response to it. The Government will not pay for the preparation of any information submitted or for the Government’s use of such information. No basis for claims against the U.S. Government shall arise as a result of a response to this RFI or from the Government’s use of such information.
The NCI looks forward to your input and we hope that you will share this RFI document with your colleagues for their input.
Kristine Willis, Ph.D.
Division of Cancer Biology (DCB)
National Cancer Institute (NCI)